Vertaling van "advanced clinical development to " (Frans → Nederlands) :

folding and its platform for drug and target discovery, the company is building a pipeline, initially for neurodegenerative and respiratory conditions. FoldRx’s pipeline includes a program in advanced clinical development to treat genetic neurologic and cardiovascular disorders, Transthyretin (TTR) Amyloid Polyneuropathy (ATTR-PN) and TTR Amyloid Cardiomyopathy (ATTR-CM), and a discovery program in cystic fibrosis, Parkinson’s, and Huntington’s disease based on its broad, proprietary, yeast-based drug discovery platform.
FoldRx is a development and discovery company focusing on first-in-class, disease-modifying, small molecule therapeutics to treat diseases of protein misfolding and aggregation (amyloidosis) based on the pioneer work of its scientific founders, Jeffery Kelly (The Scripps Research Institute) and Susan Lindquist (Whitehead Institute).

Interview avec Mace Rothenberg, Senior Vice President Clinical Development and Medical Affairs – Pfizer Oncology
Interview met Mace Rothenberg, Senior Vice President Clinical Development and Medical Affairs – Pfizer Oncology

Mace Rothenberg, Senior Vice President, Clinical Development and Medical Affairs au sein de Pfizer, le confirme en ces termes : « On peut incontestablement affirmer, sans risque de se tromper, que la médecine anticancéreuse a un rôle pionnier dans la médecine personnalisée.
Mace Rothenberg, Senior Vice President, Clinical Development and Medical Affairs bij Pfizer, is het daarmee eens: “Men kan met zekerheid zeggen dat de tumorgeneeskunde een pioniersrol speelt in de evolutie naar een gepersonaliseerde geneeskunde.

This release contains forward-looking information about an agreement by Pfizer to acquire FoldRx, and about FoldRx’s product candidate tafamidis, its other clinical and preclinical development programs and its technology platform, including their potential benefits, that involves substantial risks and uncertainties.
DISCLOSURE NOTICE: The information contained in this release is as of September 1, 2010. Pfizer assumes no obligation to update forward-looking statements contained in this release as the result of new information or future events or developments.

Analyse de: ‐ Mitchell SL, Teno JM, Kiely DK et al. The Clinical Course of Advanced Dementia.
Bespreking van: – Mitchell SL, Teno JM, Kiely DK et al. The Clinical Course of Advanced Dementia.

NEW YORK , N.Y., December 12 - Pfizer Inc. announced that Prevenar 13* (Pneumococcal polysaccharide conjugate vaccine [13-valent, adsorbed]) was introduced into the first childhood immunization program for pneumococcal disease (PD) in the developing world under the auspices of the Advance Market Commitment (AMC) when Nicaragua launched its program today .
NEW YORK , N.Y., December 12 - Pfizer Inc. announced that Prevenar 13* (Pneumococcal polysaccharide conjugate vaccine [13-valent, adsorbed]) was introduced into the first childhood immunization program for pneumococcal disease (PD) in the developing world under the auspices of the Advance Market Commitment (AMC) when Nicaragua launched its program today .

l’évaluation des pratiques cliniques & guideline development (Good Clinical Practice)
Analyse klinische praktijk en ontwikkeling klinische praktijkrichtlijnen (Good Clinical Practice)

1. [PPT] Le poster " Development, Implementation and Evaluation of the Activity of Clinical Pharmacy through the Results of 54 Pilot Projects" (R.
1. [PDF] De poster " Development, Implementation and Evaluation of the Activity of Clinical Pharmacy through the Results of 54 Pilot Projects" (R.

21. Réseau des Comités Médicopharmaceutiques : Development, Implementation and Evaluation of the Activity of Clinical Pharmacy through the Results of 54 Pilot Projects (PDF)
21. Netwerk MFC : Development, Implementation and Evaluation of the Activity of Clinical Pharmacy through the Results of 54 Pilot Projects (PDF)